目的：探讨贝伐珠单抗联合化疗治疗复治晚期非鳞非小细胞肺癌（ NSCLC）的疗效及安全性。方法收集本院2010年5月至2014年7月经病理证实符合入选标准的84例复治晚期NSCLC患者，接受贝伐珠单抗联合化疗方案治疗，化疗2个周期后按照实体瘤疗效评价标准（ RECIST 1�0）评价疗效，按照美国国立癌症研究所制定的通用药物毒性标准3�0版评价不良反应，采用Kaplan⁃Meier法进行生存分析。结果84例患者均可评价疗效且无CR病例，其中获PR 12例，SD 42例，PD 30例，有效率和疾病控制率分别为14�8％和64�8％；全组的中位无进展生存期和总生存期分别为3�8个月和8�8个月；不良反应主要为骨髓抑制、高血压、肝功能损害、皮疹等，以1、2级为主。结论贝伐珠单抗联合化疗治疗晚期非鳞NSCLC的疗效好，不良反应轻，值得临床上推广。%Objective To explore the therapeutic effect and safety of bevacizumab combined with chemotherapy in previously treated advanced patients with non⁃small cell lung cancer ( NSCLC) . Methods In this study, 84 patients pathologically in accordance with the feature of advanced NSCLC were treated with bevacizumab combined with chemotherapy from May 2010 to July 2014. The cur⁃ative effect was analyzed according to Response Evaluation Criteria in Solid Tumors ( RECIST) 1�1 every 2 cycles. The National Cancer Institute Common Toxicity Criteria ( NCI⁃CTC) version 3�0 was employed to evaluate the adverse reaction. Survival analysis was per⁃formed using Kaplan⁃Meier method. Results All the 84 patients were evaluable for response. There were no CR cases, 12 cases of PR, 42 cases of SD and 30 cases of PD with the response rate and disease control rate of 14�8% and 64�8%. The median progression free survival and overall survival were 3�8 months and 8�8 months, respectively. The main adverse reactions of bevacizumab were hy⁃pertension, bone marrow suppression, liver function damage and skin rash, manifested most as degree 1⁃2 but rarely degree 3⁃4. Con⁃clusion It was effective and safe for advanced NSCLC patients treated with bevacizumab combined with chemotherapy.
展开▼
